Bemcentinib
BerGenBio $BGBIO upgraded target price to 86 NOK from ArcticSecQuote:
"Bemcentinib has shown effect against SARS-CoV-2 (coronavirus) in animal models and has been selected as the first of six drugs to be fast-tracked in the new UK initiative (ACCORD) to enter a phase 2 study directly.
Although there are many uncertainties around valuing this opportunity, we estimate the new indication adds NOK 21/share, with a new TP of NOK 86.
Read-out of the phase 2 study is expected in approx. 6 weeks. Developments will be followed closely."
Source:
www.research-tree.com
